RGT-61159
RGT-61159 Phase 1a/b
Rgenta Therapeutics · Phase 1 · Active, not recruiting · Enrollment 105
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| RGT-61159 at or below RP2D | R/R ACC, evaluable (n = 39) | at or below RP2D (mixed doses) | Single arm | n/r | disease control rate: 84.6%, ASCO 2026, preliminarypartial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending |